An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients

Acta Psychiatr Scand. 1986 Nov;74(5):519-23. doi: 10.1111/j.1600-0447.1986.tb06277.x.

Abstract

Seven psychotic inpatients (two women and five men) aged between 18 and 74 years, treated with neuroleptic and antiparkinson drugs, participated in a double-blind study with 1/3 DDD (Defined Daily Dose) of procyclidine, orphenadrine, or trihexyphenidyl hydrochloride against placebo. Euphoric effects were scored on a self-rating scale and extrapyramidal side-effects on the Simpson-Angus rating scale at drug administration and 1, 3 and 6 h thereafter. With regard to euphoric effect, there was a significant (P less than 0.02) difference between start and end point (0 and 6 h) for placebo but not for the active antiparkinson drugs. There was no significant difference in extrapyramidal side-effects. No preference of drug was found, and it was not possible to recognize the patient's own drug among the tested drugs. Side-effects from the antiparkinson drugs were also measured prior to the administration. Five patients did not return to their earlier antiparkinson drugs after the study.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antipsychotic Agents / adverse effects
  • Double-Blind Method
  • Euphoria*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Orphenadrine / adverse effects
  • Orphenadrine / pharmacology*
  • Parkinson Disease, Secondary / drug therapy*
  • Procyclidine / adverse effects
  • Procyclidine / pharmacology*
  • Psychotic Disorders / drug therapy*
  • Pyrrolidines / pharmacology*
  • Trihexyphenidyl / adverse effects
  • Trihexyphenidyl / pharmacology*

Substances

  • Antipsychotic Agents
  • Pyrrolidines
  • Trihexyphenidyl
  • Orphenadrine
  • Procyclidine